Represents the length of time the collaborative agreement is in effect subject to terms specified within the agreement.

No definition available.

Name:	sva_CollaborativeArrangementTermOfAgreement
Namespace Prefix:	sva_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaborative arrangements and non collaborative arrangement license issue royalty

+ References

No definition available.

+ Details

Name:	sva_CollaborativeArrangementsAndNonCollaborativeArrangementLicenseIssueRoyalty
Namespace Prefix:	sva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Collaborative arrangements and non collaborative arrangement license royalty payments upon achievement of each benchmark.

+ References

No definition available.

+ Details

Name:	sva_CollaborativeArrangementsAndNonCollaborativeArrangementLicenseRoyaltyPaymentsUponAchievementOfEachBenchmark
Namespace Prefix:	sva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the amount of collaborative arrangements and noncollaborative arrangement entrance fees and milestone payments.

+ References

No definition available.

+ Details

Name:	sva_CollaborativeArrangementsAndNoncollaborativeArrangementEntranceFeesAndMilestonePayments
Namespace Prefix:	sva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the amount of licenses fees and royalties paid by the entity as per the collaboration agreement.

+ References

No definition available.

+ Details

Name:	sva_CollaborativeArrangementsAndNoncollaborativeArrangementLicensesFeesAndRoyaltiesPaid
Namespace Prefix:	sva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the amount of milestone payments that will be made by the entity as per the collaboration agreement.

+ References

No definition available.

+ Details

Name:	sva_CollaborativeArrangementsAndNoncollaborativeArrangementMilestonePayments
Namespace Prefix:	sva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the amount of milestone payments incurred by the entity as per the collaboration agreement.

+ References

No definition available.

+ Details

Name:	sva_CollaborativeArrangementsAndNoncollaborativeArrangementMilestonePaymentsIncurred
Namespace Prefix:	sva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents the amount of milestone payments incurred by the entity for the collaboration agreement before amendment.

+ References

No definition available.

+ Details

Name:	sva_CollaborativeArrangementsAndNoncollaborativeArrangementMilestonePaymentsIncurredForAgreementBeforeAmendment
Namespace Prefix:	sva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents the amount of milestone payments incurred by the entity for the amended collaboration agreement.

+ References

No definition available.

+ Details

Name:	sva_CollaborativeArrangementsAndNoncollaborativeArrangementMilestonePaymentsIncurredForAmendedAgreement
Namespace Prefix:	sva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents the amount of non-refundable annual royalty payable by the entity as per the agreement.

+ References

No definition available.

+ Details

Name:	sva_CollaborativeArrangementsAndNoncollaborativeArrangementNonRefundableAnnualRoyalty
Namespace Prefix:	sva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the amount that will be paid by the entity as per the amended collaboration agreement for transfer of additional serotypes and related technology.

+ References

No definition available.

+ Details

Name:	sva_CollaborativeArrangementsAndNoncollaborativeArrangementPaymentForTransferOfAdditionalSerotypesAndRelatedTechnology
Namespace Prefix:	sva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Entrance fee recorded during the period as research and development expense.

+ References

No definition available.

+ Details

Name:	sva_EntranceFeeRecordedAsResearchAndDevelopmentExpense
Namespace Prefix:	sva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Expense related to license agreement.

+ References

No definition available.

+ Details

Name:	sva_ExpenseRelatedToLicenseAgreement
Namespace Prefix:	sva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Milestone fee recorded during the period as research and development expense.

+ References

No definition available.

+ Details

Name:	sva_MilestoneFeeRecordedResearchAndDevelopmentExpenses
Namespace Prefix:	sva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number of additional serotypes signed for transfer.

+ References

No definition available.

+ Details

Name:	sva_NumberOfAdditionalSerotypesSignedForTransfer
Namespace Prefix:	sva_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of doses of vaccines.

+ References

No definition available.

+ Details

Name:	sva_NumberOfDosesOfVaccines
Namespace Prefix:	sva_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of payment made for use of product in research and development expense.

+ References

No definition available.

+ Details

Name:	sva_PaymentMadeRecordedAsResearchAndDevelopmentExpense
Namespace Prefix:	sva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the royalty payments on net sales, expressed as a percentage, under collaborative agreement.

+ References

No definition available.

+ Details

Name:	sva_RoyaltyPaymentOnNetSales
Namespace Prefix:	sva_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_AccruedRoyaltiesCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585

+ Details

Name:	us-gaap_PaymentsToAcquireProductiveAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.3)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

+ Details

Name:	us-gaap_RoyaltyExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=sva_TianjingCanSinoBiotechnologyIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=sva_TechnologyTransferAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=sva_TechnologyTransferAgreementThirdAmendmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=sva_NationalInstituteOfHealthMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=sva_PatentLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=sva_MedimmuneLlcMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=sva_HFiveNOneLicensesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=sva_InstituteForTranslationalVaccinologyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=sva_SabinInactivatedPolioVaccineMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration Agreements - Additional Information (Details) € in Millions					12 Months Ended
	Apr. 03, 2014	Dec. 14, 2011 USD ($) Serotype	Aug. 18, 2009 USD ($)	Mar. 12, 2009 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2018 EUR (€)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2016 EUR (€)	Dec. 31, 2014 USD ($)	Dec. 31, 2014 EUR (€)	Dec. 31, 2013 USD ($) Dose	Dec. 31, 2012 USD ($)
Accrued royalties, current					$ 9,000		$ 0	$ 8,000
Milestone fee recorded research and development expenses					611,000	€ 0.5		568,000	€ 0.5
Payments to acquire productive assets					0		87,000	84,000
Tianjing Can Sino Biotechnology Inc \| Technology Transfer Agreement
Term of Collaboration Agreement				8 years
Collaborative arrangements and noncollaborative arrangement payment for transfer of additional serotypes and related technology		$ 300,000
Number of additional serotypes signed for transfer \| Serotype		6
Collaborative arrangements and noncollaborative arrangement milestone payments incurred								1,200,000
Collaborative arrangements and noncollaborative arrangement milestone payments incurred for agreement before amendment								1,000,000
Collaborative arrangements and noncollaborative arrangement milestone payments incurred for amended agreement										$ 200,000
Tianjing Can Sino Biotechnology Inc \| Technology Transfer Agreement \| Maximum [Member]
Collaborative arrangements and noncollaborative arrangement milestone payments				$ 3,000,000
Royalty payment on net sales				10.00%
Tianjing Can Sino Biotechnology Inc \| Technology Transfer Agreement \| Minimum [Member]
Royalty payment on net sales				6.00%
Tianjing Can Sino Biotechnology Inc \| Technology Transfer Agreement Third Amendment
Collaborative arrangements and noncollaborative arrangement milestone payments incurred					0		0	300,000
National Institute of Health \| Patent License Agreement
Term of Collaboration Agreement			8 years
Collaborative arrangements and noncollaborative arrangement license issue royalty			$ 80,000
Collaborative arrangements and noncollaborative arrangement license royalty payments upon achievement of each benchmark					330,000
Royalty expense					16,000		0	$ 0
National Institute of Health \| Patent License Agreement \| Maximum [Member]
Royalty payment on net sales			4.00%
National Institute of Health \| Patent License Agreement \| Minimum [Member]
Royalty payment on net sales			1.50%
Collaborative arrangements and noncollaborative arrangement non refundable annual royalty			$ 8,000
Medimmune LLC \| H5N1 Licenses
Collaborative arrangements and noncollaborative arrangement milestone payments incurred					$ 9,900,000
Collaborative arrangements and noncollaborative arrangement licenses fees and royalties paid													$ 3,400,000
Accrued royalties, current												$ 1,036,000
Number of doses of vaccines from Chinese government \| Dose												3,000,000
Institute for Translational Vaccinology
Term of Collaboration Agreement	50 years
Collaborative arrangements and noncollaborative arrangement milestone payments \| €											€ 1.5
Collaborative arrangements and noncollaborative arrangement entrance fees and milestone payments										2,406,000
Entrance fee recorded as research and development expense										665,000	0.5
Expense incurred or paid							$ 0
Institute for Translational Vaccinology \| Sabin Inactivated Polio Vaccine
Payment made recorded as research and development expense										$ 125,000	€ 94.0